CLAIM CARD
Several unresolved questions constrain the translational potential of Carnosine anti glycation. First, the duration of most trials — typically under 12 weeks — may be insufficient to detect effects on endpoints such as vascular stiffness, renal function, or cognitive trajectories that unfold over years or decades. Second, population specificity poses a challenge: carnosine supplementation showed benefits in younger cognitive cohorts (OToole 2025) but not uniformly across age groups, and the relevance of AGE-reduction strategies may differ between diabetic and non-diabetic populations. Third, the tension between positive findings in immune-inflammation outcomes (Sukon 2024) and null mechanistic signals (Lee 2026) illustrates the broader difficulty of translating cell-level anti-glycation effects to clinical inflammation endpoints. Whether Carnosine anti glycation can deliver meaningful benefit in aging populations will require trials that extend beyond surrogate markers (Ioannidis 2005) to functional and hard clinical endpoints.
Evidence grade: exploratory
Contradiction status: none
Publication: 9f7abff5-de87-4959-b080-10eac9863ba7
Provenance: Derivation Web chain
Citation Support
source_1Movahedian 2025source_2Kopytek 2025source_3Kabthymer 2024source_4Li 2025source_5Dahlen 2025